Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Health technology assessment (Winchester, England) - 1 Oct 2004

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J

Abstract excerpt

OBJECTIVES: To assess the clinical-effectiveness and cost-effectiveness of pegylated interferon-alpha combined with ribavirin in the treatment of chronic hepatitis C. DATA SOURCES: Electronic databases, reference lists of retrieved reports, and the industry submissions to the National Institute for Clinical Excellence. REVIEW METHODS: Sources were rigorously searched and studies were selected that met the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Quality-Adjusted Life Years

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Source

Identifiers

PMID: 15461877
DOI: 10.3310/hta8390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.PMID 15461877Read ↗

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Semantic proximity Read ↗

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.Semantic proximity Read ↗

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.Semantic proximity Read ↗

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.Semantic proximity Read ↗

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.Semantic proximity Read ↗

Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Semantic proximity Read ↗

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.Semantic proximity Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.